Good morning, everyone, and how are you today? We are doing quite nicely, thank you, helped by an unexpectedly quiet Pharmalot campus, which is benefiting from a shiny sun and deliciously cool breeze. May is a delightful month, yes? Nonetheless, we can stare out the window just so long. After all, there is much to do. So, time to get cracking. Here are some tidbits to help you on your own journey today. Hope all goes well and, as always, do keep in touch. We enjoy your thoughts. …

Takeda Pharmaceutical (TKPHF), which is looking to pay down debt following its megadeal for Shire, is selling the Xiidra eye drug to Novartis (NVS) and the TachoSil surgical patches and sealants to the Johnson & Johnson (JNJ) Ethicon unit, The Wall Street Journal notes. The deals, expected to close in the second half of the year, would bring Takeda $3.8 billion in cash up front and up to $1.9 billion in additional payments from Novartis subject to certain milestones being met. Takeda has said it would sell about $10 billion worth of assets to pay down debt.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy